Pediatric severe traumatic brain injury (TBI) is the leading cause of death and disability in children ages 1-14 years old. There are no effective therapies to treat secondary brain injury and the post-injury response of CNS apoptosis and neuroinflammation. This study is a follow-up trial from a previously performed Phase I trial that demonstrated the safety and potential CNS structural preservation effect of intravenous autologous bone marrow mononuclear cells (BMMNC) after severe TBI in children. (Cox, 2011) The study is designed as a prospective, randomized, placebo controlled, blinded Phase 2 safety/biological activity study. The investigators hope to determine the effect of intravenous infusion of autologous BMMNCs on brain structure and neurocognitive/functional outcomes after severe TBI in children.
Study Design: Multicenter, randomized, blinded, placebo controlled, Bayesian adaptive dose escalation design. Study Intervention: Single dose administered within 48 hours from time of injury. Controls will undergo a sham harvest and receive similarly labeled/external appearance and volume of 0.9% NaCl. BMMNC's will be harvested and undergo processing under cGMP conditions to obtain 6x10\^6 cells/kg or 10x10\^6 cells/kg weight. The cellular product/placebo will be infused within 48 hours of injury. Safety Monitoring \& Follow-Up: Subjects will be monitored for infusion related toxicity post-infusion through hospital discharge and follow-up return study visits. Laboratory and imaging studies will be repeated at the 1, 6, and 12-month follow-up visits. A medical safety monitor (MSM) will review blinded SAE reports following post-infusion Day 14 for each subject in real time to ensure good clinical practice and to quickly identify safety concerns. The MSM will remain blinded to the treatment assignment, unless the NINDS appointed DSMB approves unblinding.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
47
BMMNC infusion of either 6x10\^6 cells/kg or 10x10\^6 cells/kg weight.
Placebo infusion of 0.9% Sodium Chloride
Phoenix Children's Hospital I University of Arizona
Phoenix, Arizona, United States
The University of Texas Health Science Center at Houston
Houston, Texas, United States
brain white matter and gray matter structural preservation on diffusion tensor magnetic resonance imaging (DTMRI)
DTMRI quantitative indices of both macro and microscopic integrity will be evaluated and compared to DTMRI of immediate post-injury treated and non-treated controls.
Time frame: one year post infusion
CNS white matter and gray matter preservation in regions of interest and improves functional and neurocognitive deficits in children after TBI
Time frame: one year post infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.